244 related articles for article (PubMed ID: 5042372)
1. Peripheral aromatic L-amino acids decarboxylase inhibitor in parkinsonism. II. Effect on metabolism of L-2- 14 C-dopa.
Bianchine JR; Messiha FS; Hsu TH
Clin Pharmacol Ther; 1972; 13(4):584-94. PubMed ID: 5042372
[No Abstract] [Full Text] [Related]
2. Effects of peripheral aromatic L-amino acids decarboxylase inhibitor on L-(2- 14 C)-3,4-dihydroxyphenylalanine metabolism in man.
Messiha FS; Hsu TH; Bianchine JR
Biochem Pharmacol; 1972 Aug; 21(15):2144-7. PubMed ID: 4645885
[No Abstract] [Full Text] [Related]
3. [Modifications of catecholamine metabolism under the effect of a decarboxylase inhibitor associated with L-dopa and desipramine in patients with depressive and parkinsonian syndromes].
Geissbuhler F; Bartholini G; Gaillard JM; Tissot R
Encephale; 1971; 60(3):189-209. PubMed ID: 5119348
[No Abstract] [Full Text] [Related]
4. [Parkinsonism and plasma metabolism of dihydroxyphenylalanine administered with an inhibitor of decarboxylase].
Geissbühler F; Constantinidis J; Eisenring JJ; Krassoievitch M; Yanniotis G; Tissot R
Clin Chim Acta; 1971 Jun; 33(1):111-5. PubMed ID: 5097993
[No Abstract] [Full Text] [Related]
5. [Potentiation of L-Dopa in parkinsonism by means of an inhibitor of peripheral decarboxylation].
Court J; Kase JC; Mena I; Palacios E
Rev Med Chil; 1973 Jun; 101(6):452-5. PubMed ID: 4764560
[No Abstract] [Full Text] [Related]
6. Levodopa in Parkinsonism: potentiation of central effects with a peripheral inhibitor.
Papavasiliou PS; Cotzias GC; Düby SE; Steck AJ; Fehling C; Bell MA
N Engl J Med; 1972 Jan; 286(1):8-14. PubMed ID: 4550085
[No Abstract] [Full Text] [Related]
7. Studies on the metabolism and excretion of L-3,4-dihydroxyphenylalanine (L-DOPA) in human beings by gas chromatography.
Imai K; Sugiura M; Kubo H; Tamura Z; Oya K
Chem Pharm Bull (Tokyo); 1972 Apr; 20(4):759-64. PubMed ID: 5045616
[No Abstract] [Full Text] [Related]
8. Effect of L-aromatic amino acid decarboxylase inhibition on metabolism of dihydroxyphenylalanine by isolated perfused rat liver.
Tyce GM; Owen CA
Biochem Pharmacol; 1972 Nov; 21(22):2977-89. PubMed ID: 4649349
[No Abstract] [Full Text] [Related]
9. Administration of a peripheral decarboxylase inhibitor with L-dopa to depressed patients.
Goodwin FK; Brodie HK; Murphy DL; Bunney WE
Lancet; 1970 May; 1(7653):908-11. PubMed ID: 4191547
[No Abstract] [Full Text] [Related]
10. The effect of methyldopa on the excretion of catecholamines in patients with extrapyramidal disorders.
Metzel A; Holldorf A; Umbach W
Confin Neurol; 1967; 29(2):78-80. PubMed ID: 5591949
[No Abstract] [Full Text] [Related]
11. Peripheral aromatic L-amino acids decarboxylase inhibitor in Parkinsonism. I. Effect on O-methylated metabolites of L-dopa-2- 14 C.
Messiha FS; Hsu TH; Bianchine JR
J Clin Invest; 1972 Feb; 51(2):452-5. PubMed ID: 5009125
[TBL] [Abstract][Full Text] [Related]
12. Modification of levodopa effect by systemic decarboxylase inhibition.
Mars H
Arch Neurol; 1973 Feb; 28(2):91-5. PubMed ID: 4683155
[No Abstract] [Full Text] [Related]
13. Block of cerebral actions of L-dopa with methyl receptor substances.
Cotzias GC; Tang L; Ginos JZ; Nicholson AR; Papavasiliou PS
Nature; 1971 Jun; 231(5304):533-5. PubMed ID: 4934569
[No Abstract] [Full Text] [Related]
14. [Selective increase of C14-catecholamines in the brain due to peripheral inhibition of decarboxylase].
Bartholini G; Pletscher A; Burkard WP
Helv Physiol Pharmacol Acta; 1967; 25(2):CR170-2. PubMed ID: 5588156
[No Abstract] [Full Text] [Related]
15. [Advantages of the combination therapy (L-Dopa and decarboxylase inhibitors) in parkinsonism].
Gattringer B; Steinhäusl H
Wien Med Wochenschr; 1972 Jun; 122(25):369-71. PubMed ID: 4558132
[No Abstract] [Full Text] [Related]
16. Dopamine: mediator of brain polysome disaggregation after L-dopa.
Weiss BF; Munro HN; Ordonez LA; Wurtman RJ
Science; 1972 Aug; 177(4049):613-6. PubMed ID: 4403139
[TBL] [Abstract][Full Text] [Related]
17. [Therapy of Parkinson's syndrome with L-dopa per os combined with a decarboxylase inhibitor (Ro 46.02)].
Tissot R; Gaillard JM; Guggisberg M; Gauthier G; De Ajuriaguerra J
Neurol Neurocir Psiquiatr; 1969; 10(1):1-25. PubMed ID: 5406970
[No Abstract] [Full Text] [Related]
18. [Urinary excretion of 3,4-dihydroxyphenyl-alanine, 3-O-methyldopa, dopamine and homovanillic acid in man. Effects of an inhibitor of decarboxylase of aromatic amino acids (Benserazide) (author's transl)].
Geissbühler F; Widmer J
J Clin Chem Clin Biochem; 1976 Nov; 14(11):543-7. PubMed ID: 1003116
[TBL] [Abstract][Full Text] [Related]
19. The metabolism of L-3-O-methyldopa, a precursor of dopa in man.
Kuruma I; Bartholini G; Tissot R; Pletscher A
Clin Pharmacol Ther; 1971; 12(4):678-82. PubMed ID: 5567811
[No Abstract] [Full Text] [Related]
20. Metabolism and absorption of L-3,4 dihydroxyphenylalanine in patients with Parkinson's disease.
Bianchine JR; Calimlim LR; Morgan JP; Dujuvne CA; Lasagna L
Ann N Y Acad Sci; 1971 Jul; 179():126-40. PubMed ID: 5285373
[No Abstract] [Full Text] [Related]
[Next] [New Search]
